Danielle Watson - 09 Jul 2025 Form 4 Insider Report for HeartSciences Inc. (HSCS)

Role: Chief Financial Officer
Signature: /s/ Danielle Watson
Issuer symbol: HSCS
Transactions as of: 09 Jul 2025
Transactions value $: $0
Form type: 4
Date filed: 11 Jul 2025, 20:56
Previous filing: 21 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Watson Danielle	Chief Financial Officer	C/O HEARTSCIENCES INC.,, 550 RESERVE STREET, SUITE 360, SOUTHLAKE	/s/ Danielle Watson	2025-07-11	0001933818

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HSCS	Stock Option (Right to Buy)	Award		+25K			25K	09 Jul 2025	Common Stock	25K	$4.37	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors.
F2	One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of October 9, 2026 and thereafter on each successive three-month anniversary of such date, such that all options shall vest on July 9, 2028 (or earlier as described below), subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Plan. These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm (subject to certain requirements) (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration, or a Change of Control (as defined in the Reporting Person's Employment Agreement (the "EA")). As of the date of this filing, such regulatory clearance has not been received.
F3	These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Equity Incentive Plan, as amended (the "Plan") or the underlying options grant agreement.

Remarks:

Chief Financial Officer